Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia

BACKGROUND: Global studies have demonstrated the efficacy and safety of blinatumomab—a BiTE(®) (bispecific T‐cell engager) targeted immuno‐oncology therapy that mediates the lysis of cells expressing CD19 in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Because limited da...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Yukio, Oh, Iekuni, Miyamoto, Toshihiro, Lee, Won‐Sik, Iida, Hiroatsu, Minami, Hironobu, Maeda, Yoshinobu, Jang, Jun Ho, Yoon, Sung‐Soo, Yeh, Su‐Peng, Tran, Qui, Morris, Joan, Franklin, Janet, Kiyoi, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292847/
https://www.ncbi.nlm.nih.gov/pubmed/34185953
http://dx.doi.org/10.1111/ajco.13609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292847/
https://www.ncbi.nlm.nih.gov/pubmed/34185953
http://dx.doi.org/10.1111/ajco.13609

Ejemplares similares